Bookings Surge and Revenue Dives: D-Wave's $100M Government Deal Comes With a Dilutionary Twist

D-Wave shares surge 13% after US government invests $100M from CHIPS Act, but existing shareholders face dilution as the funding is an equity stake, not a grant.

The US government is about to become a shareholder in D-Wave Quantum, and the market has responded with a notably selective reading of the fine print. Shares in the quantum-computing specialist rocketed more than 13% on Friday to €25.04, capping a weekly gain of nearly 43%. Yet the euphoria glosses over a critical detail in the $100 million package from Washington: the money is not a grant but an equity injection, with the company issuing common stock of equivalent value to the US Department of Commerce.

The funding, sourced from the CHIPS and Science Act, represents a milestone for the still-unprofitable firm — a lifeline to accelerate its technological roadmap. D-Wave plans to use the capital to push towards a 100,000-qubit annealing system alongside a 10,000-qubit gate-model platform. But for existing shareholders, the deal carries an immediate cost: dilution. The government’s minority stake will reduce the proportional ownership of every current investor, a price that the market has so far chosen to ignore.

The volatility surrounding the stock tells its own story. With an annualised volatility north of 148%, D-Wave remains one of the most speculative names in the quantum space. Even after last week’s surge, the shares trade about 34% below their 52-week high of roughly €38, underlining how far the recovery still has to go.

Beneath the price action lies a financial picture that defies easy categorisation. Revenue in the first quarter collapsed by 81% to just $2.9 million, a drop largely attributable to a large system sale in the prior-year period. Yet bookings — orders that have yet to convert into recognised revenue — exploded to a record $33.4 million, a staggering increase of nearly 2,000%. A separate $20 million contract with Florida Atlantic University for an Advantage2 quantum computer added further weight to the pipeline.

The disconnect between vanishing revenue and surging orders is the central riddle of the D-Wave investment case. The company’s cash position is robust — $588 million in cash and marketable securities at the end of March — and its gross margin stands at roughly 83%. But the net loss for the quarter came in at $18 million, underscoring the burn rate required to sustain R&D at this stage. The acquisition of Quantum Circuits has also turned D-Wave into a dual-platform quantum provider, adding technical breadth but also integration risk.

Analyst sentiment remains overwhelmingly positive. Thirteen analysts rate the stock a buy, with none recommending a sale. The consensus price target sits at around $35, while Rosenblatt Securities sees as much as $43. TD Cowen has identified D-Wave as one of the biggest beneficiaries of the broader federal quantum initiative, which is expected to mobilise roughly $2 billion in government resources.

Yet the deal with Washington is not yet binding. D-Wave must finalise contracts and hit specific technical milestones before the funds flow. If negotiations stall, the promised capital disappears — and the market will have to reassess the true value of the government’s equity stake. For now, the rally is fuelled by anticipation, not delivery. The coming quarters will reveal whether the bookings explosion can finally translate into cash revenue, or whether the dilution-backed funding is merely buying time in a sector where patience is running thin.